Cornea
December 2022
by Clara Chan, MD
Cornea Editor
As I compose my final introduction as the Cornea Editor for EyeWorld, I look out the window of my office and suddenly realize that the leaves have all become vibrant red, orange, and yellow in color. My son, however, still insists on wearing shorts to school, in denial that winter is around the corner here in Toronto, Canada. As much as it is human nature to resist change, in ophthalmology, this path of innovation, progression, and disruption is what keeps our field exciting and in constant evolution.
As much as it is human nature to resist change, in ophthalmology, this path of innovation, progression, and disruption is what keeps our field exciting and in constant evolution.
In the last decade, I have witnessed the advent and broad implementation of DMEK surgery, femtosecond laser cataract surgery, the titanium backplate Boston Type 1 KPro, multiple novel dry eye therapies, topography-guided PRK, trifocal IOL technology, corneal inlays, ICL implants, and the impact of a worldwide pandemic, which introduced us to virtual ophthalmology, including 3D remote surgical teaching platforms, to name a few. You can count on EyeWorld to keep you up to date.
In this issue of EyeWorld, there are articles about the impact of COVID-19 vaccines on corneal transplants, what alternatives there are with the loss of topical interferon to treat ocular surface squamous neoplasia, and endothelial cell injection therapy for decompensated corneas, with the latter being a technology that I am extremely excited about as I envision it to completely disrupt our approach to managing corneal endothelial disease.
To conclude, I want to share what an honor it has been to serve as the Cornea Editor for EyeWorld. I could not have done it without the support of the members of the Cornea Editorial Board, the other section editors, the EyeWorld staff, and all of our expert contributors. I want to warmly welcome Julie Schallhorn, MD, associate professor of ophthalmology at the University of California San Francisco, who will be the next Cornea Editor. She has an outstanding background in bioengineering, and fellowships in uveitis, cornea, and refractive surgery. It is with great excitement that I watch the seasons change and anticipate how the Cornea section of EyeWorld will continue to flourish in her hands.
ARTICLE SIDEBAR
EyeWorld would like to thank Dr. Chan for her many years of service as Cornea Editor. We appreciate the expertise and enthusiasm she has brought to the publication. We look forward to her continued involvement on the Editorial Board in the future.
